Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate

The clinical use of amifampridine phosphate for neuromuscular junction disorders is increasing. The metabolism of amifampridine occurs via polymorphic aryl N-acetyltransferase (NAT), yet its pharmacokinetic (PK) and safety profiles, as influenced by this enzyme system, have not been investigated. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Haroldsen, Peter E, Garovoy, Marvin R, Musson, Donald G, Zhou, Huiyu, Tsuruda, Laurie, Hanson, Boyd, O’Neill, Charles A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317230/
https://www.ncbi.nlm.nih.gov/pubmed/25692017
http://dx.doi.org/10.1002/prp2.99

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317230/
https://www.ncbi.nlm.nih.gov/pubmed/25692017
http://dx.doi.org/10.1002/prp2.99

Ejemplares similares